Metraipolis › archive › dc_a72480d64d4d
Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants — Europe PMC PMID:37713444
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37713444
- DOI
- 10.1371/journal.pgen.1010940
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:26:47.967Z
- SHA-256 of the archived text
9c75beae0b8bf91cea97dafdbc9d1ba9e7d5ecd6f7175050e38a2fdde1931da3- Stable URL of this page
https://metraipolis.com/documento/dc_a72480d64d4d
How to cite
Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants — Europe PMC PMID:37713444 — Europe PMC (en), https://europepmc.org/article/MED/37713444 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a72480d64d4d (Metraipolis archive dc_a72480d64d4d, sha256 9c75beae0b8bf91cea97dafdbc9d1ba9e7d5ecd6f7175050e38a2fdde1931da3)
BibTeX
@misc{dca72480d64d4d,
title = {Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants — Europe PMC PMID:37713444},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37713444},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a72480d64d4d; sha256 9c75beae0b8bf91cea97dafdbc9d1ba9e7d5ecd6f7175050e38a2fdde1931da3},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37713444. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The unknown pathogenicity of a significant number of variants found in cancer-related genes is attributed to limited epidemiological data, resulting in their classification as variant of uncertain significance (VUS). To date, Breast Cancer gene-2 (BRCA2) has the highest number of VUSs, which has necessitated the development of several robust functional assays to determine their functional significance. Here we report the use of a humanized-mouse embryonic stem cell (mESC) line expressing a single copy of the human BRCA2 for a CRISPR-Cas9-based high-throughput functional assay. As a proof-of-principle, we have saturated 11 codons encoded by BRCA2 exons 3, 18, 19 and all possible single-nucleotide variants in exon 13 and multiplexed these variants for their functional categorization. Specifically, we used a pool of 180-mer single-stranded donor DNA to generate all possible combination of variants. Using a high throughput sequencing-based approach, we show a significant drop in the frequency of non-functional variants, whereas functional variants are enriched in the pool of the cells. We further demonstrate the response of these variants to the DNA-damaging agents, cisplatin and olaparib, allowing us to use cellular survival and drug response as parameters for variant classification. Using this approach, we have categorized 599 BRCA2 variants including 93-single nucleotide variants (SNVs) across the 11 codons, of which 28 are reported in ClinVar. We also functionally categorized 252 SNVs from exon 13 into 188 functional and 60 non-functional variants, demonstrating that saturation genome editing (SGE) coupled with drug sensitivity assays can enhance functional annotation of BRCA2 VUS. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS genetics, 2023 (prima pubblicazione 2023-09-15). Identificativi: PMID 37713444 · PMCID PMC10529611 · DOI 10.1371/journal.pgen.1010940. Descrittori MeSH principali: Breast Neoplasms; Gene Editing. Pagina: https://europepmc.org/article/MED/37713444 — https://doi.org/10.1371/journal.pgen.1010940. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:59:26.162Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.